Posted by Michael Wonder on 04 May 2022
Imfinzi plus chemotherapy granted priority review in the US for patients with locally advanced or metastatic biliary tract cancer based on TOPAZ-1 Phase III trial
4 May 2022 - First Phase 3 trial in this setting to show improved overall survival with an immunotherapy added to chemotherapy over standard-of-care chemotherapy alone.
AstraZeneca’s supplemental Biologics License Application for Imfinzi (durvalumab), in combination with standard care chemotherapy, has been accepted and granted priority review in the US for patients with locally advanced or metastatic biliary tract cancer.
